The spindle assembly checkpoint (SAC) is a 'wait-anaphase' mechanism that has evolved in eukaryotic cells in response to the stochastic nature of chromosome-spindle attachments. In the recent past, different aspects of the SAC regulation have been described. However, the role of microRNAs in the SAC is vaguely understood. We report here that Mad1, a core SAC protein, is repressed by human miR-125b. Mad1 serves as an adaptor protein for Mad2 -which functions to inhibit anaphase entry till the chromosomal defects in metaphase are corrected. We show that exogenous expression of miR-125b, through downregulation of Mad1, delays cells at metaphase. As a result of this delay, cells proceed towards apoptotic death, which follows from elevated chromosomal abnormalities upon ectopic expression of miR-125b. Moreover, expressions of Mad1 and miR-125b are inversely correlated in a variety of cancer cell lines, as well as in primary head and neck tumour tissues. We conclude that increased expression of miR-125b inhibits cell proliferation by suppressing Mad1 and activating the SAC transiently. We hypothesize an optimum Mad1 level and thus, a properly scheduled SAC is maintained partly by miR-125b.
MicroRNAs (miRNAs) are small (B22 nucleotides) noncoding RNAs that modulate gene expression through translational inhibition or messenger RNA (mRNA) degradation. 1 A single miRNA can target hundreds of genes and hence, it is predicted that miRNAs regulate expression of most of the protein-coding genes in humans. 2 Currently, about 2000 miRNAs have been identified in humans 3 (http://www.mirbase.org). Accumulating evidence suggest that miRNAs have a critical role in cell proliferation and survival, 4, 5 defects in which form one of the hallmarks of cancer. The emerging view is that deregulated miRNA expression occurs frequently in diverse cancer types. In fact, miRNA expression profiles are distinct biomarkers for classifying human cancers and identifying tumour-tissue origin. 6, 7 These studies highlight the need for elucidating miRNA function in tumorigenic pathways. 4 Presently, however, experimentally validated targets of miRNAs affecting cell survival are few.
Chromosomal instability (CIN) has a key role in aneuploidy and tumorigenesis, 8 where as aneuploidy is known to frequently result from a defective mitotic checkpoint. 9 In this context, spindle assembly checkpoint (SAC) is crucial to ensure fidelity of chromosome segregation during mitosis.
Any defect in kinetochore-spindle attachment between sister chromatids fails to satisfy SAC as a result of which metaphase remains halted until the defect is corrected. 10 Once all chromatids are bi-oriented at metaphase, E3 ubiquitin-ligase anaphase-promoting complex/cyclosome (APC/C) catalyses the proteasomal degradation of securin, an inhibitory chaperone of separase. Activated separase then cleaves the cohesin complex required for the physical linkage of sister chromatids. Owing to loss of cohesion, separated chromatids move to opposite spindle poles and cells enter anaphase. 11, 12 Furthermore, APC/C activity depends on an adaptor-protein Cdc20 (cell division cycle 20). 13 When SAC is 'on', Cdc20 remains sequestered by Mad2 and BubR1/Bub3 in the form of mitotic checkpoint complex (MCC), owing to which, APC/C remains inactive. Premature anaphase progression is thus prevented by the 'wait-anaphase' signal generated from the diffusible MCC. 10 In this context, one of the first events in SAC activation is the recruitment of an adaptor protein Mad1 to the kinetochore. Mad1 is crucial in Mad2-transportation from cytosol to nucleus and also in its kinetochore localization. Cdc20 (C-Mad2)). Mad1 traps O-Mad2 and this Mad1-CMad2 complex gets transported to unoccupied kinetochores. Bound Mad2 functions as template for conversion of other O-Mad2 molecules to C-Mad2 that can then bind Cdc20. Moreover, Mad1-C-Mad2 complex facilitates further interaction of Cdc20 and Mad2 away from kinetochores, thus providing scope for checkpoint signal-amplification. 12 The importance of Mad1 in regulating SAC is accentuated by the observation that excess Mad1 reduces free-Mad2 level in Xenopus extracts, 15 and weakens SAC by disrupting mitotictiming. 16 Conversely, excess Mad2 can arrest cells in metaphase, in spite of all chromosomes being bi-oriented successfully. 15 This underlines the need for a proper Mad1/ Mad2 ratio to maintain the integrity of SAC. 15 Head and neck/oral cancer (HNOC) is the sixth most common cancer worldwide. In the Indian subcontinent, it comprises of about 50% of all cancers. 17 CIN is a consistent property of primary head and neck tumours, 18 which makes it pertinent to describe SAC defects in HNOC. Meanwhile, 14 miRNAs are reported to be downregulated, while 29 are upregulated in HNOC. 19 To the best of our knowledge, the role of miRNAs in SAC regulation has not been elucidated yet.
In the present study, we have identified MAD1 (mitoticarrest deficient) as a novel target of human miR-125b, a downregulated miRNA in HNOC. Importantly, we show in an oral cancer cell line model that this regulation of Mad1 delays mitotic exit by transient activation of SAC. This delay results in accumulation of CIN, which culminates in apoptotic cell death. We have also verified the expression status of miR-125b and Mad1 in HNOC patients to obtain the in vivo relevance of the cell line observations.
Results

The 3
0 untranslated region (UTR) of MAD1 is a putative target of hsa-miR-125b. The in silico strategy to identify miRNAs that exhibit altered expression in HNOC and their putative mitotic targets has been illustrated (Supplementary Figure S1 ). Online target prediction of 43 miRNAs deregulated in HNOC (29 upregulated and 14 downregulated) 19 by miRBase gave us an initial data set of a large number of putative targets (Supplementary Table S1 ). Neumann et al. 20 have reported a number of genes, whose knockdown lead to one or more mitotic defects. We used these data to identify mitotic genes from the predicted targets listed in Supplementary Table S1 (Supplementary Table S2 ). Next, differential expression of this set of genes was analysed in HNOC using the Oncomine data set for nine studies (Supplementary Table S3 ). These genes were further filtered on the basis of, (1) experimentally validated mitotic roles and (2) inverse relation with the corresponding miRNA with respect to their expressions in HNOC (Supplementary Table  S4 ). This data set revealed that the essential SAC gene, MAD1, is a potential target of Homo sapiens miRNA (hsamiR)-125b. Indeed, RNAhybrid revealed that MAD1 has a miR-125b recognition site at 3 0 UTR position 3-17 ( Figure 1a and Supplementary Figure S2) . Simultaneously, it was found that Mad1 levels are elevated in various cancers including HNOC (Figure 1b and Supplementary Table S5 ). This prompted us to select MAD1 as gene of interest.
miR-125b expression is inversely correlated with Mad1 expression in human oral cancer cell lines. It is reported that miR-125b is downregulated in squamous cell carcinoma (SCC) cell lines. 21 Initially, we tested and reconfirmed that miR-125b expression is much lower in two SCC cell lines, UPCI:SCC084 and UPCI:SCC131, than in normal oral epithelial cells (Figure 1c) . Conversely, we observed that MAD1 transcript levels were higher in these cell lines (Figure 1d ). Moreover, this inverse expression pattern between MAD1 and miR-125b was also observed in other cancer cell lines (Figures 1c and d) . Hence, UPCI:SCC084 cell line was chosen to study the possible role of miR-125b in MAD1 regulation.
miR-125b negatively regulates MAD1 expression by binding to its 3 0 UTR. To validate whether MAD1 is a bona fide target of miR-125b, we transfected UPCI:SCC084 cells with increasing doses of miR-125b expression plasmid (Supplementary Figure S3A) and measured the mRNA and protein levels of MAD1. We found that MAD1 transcript levels decreased in a dose-dependent manner indicating that miR125b regulates MAD1 post-transcriptionally (Figure 2a) . Concordantly, Mad1 protein levels also declined upon ectopic miR-125b expression (Figure 2b and Supplementary Figure S3B ). That ectopic miR-125b suppressed MAD1 transcript levels was checked in other cell lines (HepG2 and HCT116) and similar observations were made (Supplementary Figures S3C and D) . Additionally, specificity of this interaction was supported by the observation that levels of another SAC gene BUB3 (budding uninhibited by benzimidazole; that does not have a recognition site for miR125b) remained unaffected by miR-125b (Figures 2c and d and Supplementary Figure S4A ). On the other hand, Mad1 levels also remained unaltered in presence of another unrelated miRNA miR-133b, which does not have a binding site on MAD1 (Figures 2e and f and Supplementary Figure  S4B) . Next, we co-transfected UPCI:SCC084 and HepG2 cells with either pSB-MAD1/3 0 UTRLuc (Figure 3a ) or pSB-MAD1/ 3 0 UTRMutLuc (Figure 3b ) with increasing doses of miR-125b and measured the luciferase (Luc) activity. As expected, a concordant dose-dependent decrease in Luc activity was observed for the 3 0 UTR containing wild-type miR-125b recognition site (Figure 3c and Supplementary Figure S5 ). In contrast, there was no significant change in Luc activity for mutant (Mut) MAD1-3 0 UTR (Figure 3d ). To complement these observations, we co-transfected UPCI:SCC084 cells with antisense inhibitor against miR-125b along-with the miRNA and pSB-MAD1/3 0 UTRLuc. Suitably, miR-125b could not bind to its target site and consequently, was unable to suppress Luc activity (Figure 3e ). Overall, these results prove that miR-125b binds to MAD1-3 0 UTR and specifically represses its expression.
Ectopic miR-125b delays mitotic exit through MAD1 repression. We next investigated the functional consequences of MAD1 repression by miR-125b. As Mad1 is a core factor in SAC regulation, initially we examined the pattern of mitotic progression of UPCI:SCC084 cells with ectopic miR-125b. This was done in three different ways in cells synchronized by thymidine treatment and released from G1 block (Figure 4a) . First, FACS analysis of vectortransfected cells revealed that their peak accumulation at G2/M phase (62.42%) occurred at 6 h post-release. By 10 h from release, percentage of cells in G2/M reduced to 32.32% (Figure 4b and Supplementary Figure S6 , upper panels). In comparison, 67.36% of cells overproducing miR-125b were in G2/M at 8 h from release, and remained marginally changed (65.34%) even at 10 h post-release ( Figure 4b and Supplementary Figure S6 , lower panels). Second, we followed the mitotic progression by monitoring the levels of two marker proteins, cyclinB1 and phosphorylated-histone H3 (p-H3). For vector-transfected cells, cyclinB1 and p-H3 levels peaked at 6 h post-release, after which they began to decline, reflecting mitotic exit (Figure 4c , left panel and graphs). In contrast, levels of both proteins were maximal at 8 h post-release upon ectopic miR-125b expression and little degraded even at the 10 h time-point implying that cells were still in mitosis (Figure 4c , middle panel and graphs). Furthermore, specificity of miR-125b-mediated mitotic regulation was proved by the observation that rapid degradation of cyclinB1 and p-H3 levels were rescued by Mad1 expression even in presence of miR-125b (Figure 4c , right panel and graphs). Besides, Cdc20 overexpression along-with miR-125b was also able to retrieve cyclinB1 degradation and p-H3 level by overriding the SAC arrest (Supplementary Figure S7) . It is noteworthy that the Mad1 expression plasmid does not carry the 3 0 UTR recognition site for miR-125b. So, Mad1 can restore the original phenotype even in presence of miR-125b. Thirdly, we evaluated the mitotic indices (MI) of miR-125b-transfected cells. The data showed that MI for miR-125b-overproducing cells was highest at the 8-h time-point (Figure 4d , third column) in comparison with vector-transfected cells, which showed highest MI at 6 h post-release (Figure 4d , middle column). Even at 10 h post-release, MI was significantly higher in presence of miR-125b than for vector-transfected cells (Figure 4d ). Moreover, many miR-125b-transfected cells were still in metaphase at the 10-h time-point, while most of Figures S8A and B) . Together, these results prove that Mad1 downregulation by miR-125b delays mitotic exit. However, previous studies have reported that partial downregulation of Mad1 leads to functional inactivation of SAC. 22 To analyse this dichotomy, we monitored the effect of miR-125b-mediated Mad1 downregulation on mitotic progression of synchronized cells in presence of the spindle poison nocodazole. Here, we followed cyclinB1 degradation pattern up to 12 h postrelease. As expected, cyclinB1 levels were stabilised for vector-treated cells as a result of nocodazole-induced mitotic arrest ( Inhibition of endogenous miR-125b accelerates mitotic exit in HCT116 cells. To find out whether the above results are reversed upon blocking endogenous miR-125b, we followed cyclinB1 degradation pattern in synchronized HCT116 cells in presence of anti-miR-125b. The HCT116 cell line was selected because, compared with other tumour cell lines, relative expression of miR-125b in this cell line was higher and MAD1 expression was low (see Figures 1c and  d ). This time, we found that cyclinB1 level was maximal at 6 h Figures S9A and B) . This implies that when endogenous level of Mad1 is increased by downregulating miR-125b, cells progress through mitosis at a faster rate. Here we also checked that the inhibitor has no effect on the levels of another SAC gene Mad2 (Supplementary Figure S10, right panel) . Incidentally, Mad2 also remained unaltered upon ectopic miR-125b expression in UPCI:SCC084 cells (Supplementary Figure S10 , left panel). These data confirmed our earlier results that mitotic exit is delayed by ectopic miR-125b, while inhibiting miR-125b switches SAC 'off' and accelerates mitotic exit.
miR-125b-induced mitotic delay initiates chromosomal abnormalities and consequent cell death. We hypothesized that miR-125b might cause chromosomal abnormalities as a consequence of the transiently activated SAC and delayed mitotic exit. Addressing this in synchronized UPCI:SCC084 cells revealed that chromosomal abnormalities were indeed pronounced in miR-125b-overproducing cells at later time-points (12 and 14 h from release) as compared with vector-transfected cells ( Figure 5 , left and 0 UTRLuc (0.1 mg), or with pSB-MAD1/3 0 UTRLuc (0.1 mg) and miR-125b expression plasmid (0.5 mg), or with pSB-MAD1/3 0 UTRLuc (0.1 mg), miR-125b expression plasmid (0.5 mg) and anti-miR-125b (20 nM). Protein lysates were prepared for Luc assay. For (c-e), data represent three independent experiments (N ¼ 3) and are shown as average±S.E. miR-125b represses MAD1 expression S Bhattacharjya et al middle panels and graph). Immunostaining of p-H3 in these abnormal chromosomes strengthened our conjecture that miR-125b-mediated delay in mitotic exit induces chromosomal aberrations (shown in greyscale images 1-6 of Figure 5 , middle panel, third and fourth rows). A number of them were found to be lagging chromosomes ( Figure 5 , middle panel, greyscale images 1, 2 and 3). Lagging chromosomes are seen as connecting threads between separating chromatids of a defective anaphase. As these chromosomes are misaligned at metaphase and forcefully enter anaphase, they retain the H3-phosphorylation, detectable by immunostaining. Besides this, ectopic Mad1 expression along-with miR-125b was also able to reverse enhanced chromosomal aberrations that were observed in presence of miR-125b, thus establishing the specificity of our results ( Figure 5 , right panel and graph). We then evaluated the phenotypic relevance of miR-125b-mediated Mad1 downregulation by examining its effect on clonogenicity and viability of UPCI:SCC084 cells. Surprisingly, the number of colonies formed after a week by miR125b-overproducing cells was significantly less than those formed by vector-transfected cells (Figures 6a and b and Supplementary Figure S11A) . Conversely, we found no significant difference in colony numbers formed by anti-miR125b-treated HCT116 cells (Supplementary Figures S11B  and C) . Similarly, MTT assay also confirmed that miR-125b reduced the viability of UPCI:SCC084 cells 72 h posttransfection (Figure 6c ). To elucidate whether apoptosis was the underlying cause for this cell death, we adopted two different approaches with miR-125b-treated UPCI:SCC084 cells. First, time-course FACS analysis after annexin V-FITC/ propidium iodide (PI) staining revealed that cells underwent considerable apoptotic death 72 h after miR-125b treatment (58.3%) as compared with vector-transfected cells (5.4%) (Figure 6d and Supplementary Figure S11D , left and middle panels). Secondly, we evaluated caspase-3 cleavage by flow cytometry using cleaved caspase-3-specific antibody. Our data indicate that caspase-3 activation increased 72 h posttransfection in presence of ectopic miR-125b (Figure 6e ). Camptothecin-treated cells (100mg/ml for 48 h) were used as positive control (Supplementary Figure S11E) . Interestingly, Mad1 co-expression was able to rescue cell viability and prevent apoptosis by miR-125b (Figures 6c, d and e and Supplementary Figure S11D, right panel) . Collectively, these data confirm that miR-125b induces chromosomal abnormalities, which in turn render the cells non-viable through apoptosis in a Mad1-specific manner.
Mad1 expression is inversely related to miR-125b expression in oral SCC tissues. Finally, we examined MAD1 and miR-125b expression profiles in 25 tumour and 20 adjacent normal tissues obtained from HNOC patients. Pathological information for these samples are provided in Supplementary Table S7 . The pooled data demonstrated that MAD1 expression was inversely related to miR-125b expression in these samples (Figure 7a ). In particular, MAD1 expression was high in 13 of 19 tumour tissues in which miR125b was downregulated (Supplementary Table S6) . A median fivefold decrease of miR-125b and fourfold increase of MAD1 expression was observed from the relativeexpression data (Supplementary Table S6 ). In addition, quantitative immunohistochemical study in 16 primary HNOC tissues confirmed that number of Mad1-expressing cells and staining-intensity were indeed greater in samples in which miR-125b levels were low and vice versa (Figure 7b (shows six representative samples) and Supplementary Table S8) . Moreover, Mad1 and miR-125b expressions in these 16 tissues were found to be significantly associated (w 2 P-value ¼ 0.017). Altogether, these results confer that the in vitro observations are reflected, at least in part, in vivo as well.
Discussion
Numerous reports suggest the role of miRNAs in cell cycle control. 23 However, recent studies have brought miRNAmediated mitotic regulation under the spotlight. 24, 25 Most recently, cyclinB1 was shown to be upregulated by miR-744 and miR-1186, prolonged overexpression of which causes CIN and inhibits tumour growth. 26 Central to mitosis is SAC, which monitors accurate chromosome segregation. Although Mad1, Mad2, BubR1/Mad3 and Bub3 are major SAC components, they have been joined by players like Cdc20, Bub1, Mps1 and AuroraB. 10 In this study, we have presented evidence that miRNAs, like bona fide SAC proteins, are capable of regulating this checkpoint. MiR-125b is a highly conserved miRNA that functions both as tumour suppressor and as oncogene depending upon cellular contexts. For instance, in hepatic carcinogenesis, miR-125b is tumour suppressive by downregulating oncogene Lin28B 27 whereas in megakaryoblastic leukaemia, it is oncogenic by repressing tumour suppressors such as ST18. 28 Interestingly, we observed that not only does miR-125b have a recognition site on MAD1-3 0 UTR, its expression is also reciprocally related with that of Mad1 in HNOC tumours and in several cancer cell lines. Subsequently, we demonstrated that miR-125b targets MAD1 specifically. Given that Mad1 is a core SAC protein, these results bring forward a new perspective of SAC regulation -that by miRNAs.
We then showed how miR-125b-mediated Mad1 downregulation affects mitotic progression of UPCI:SCC084 cells, which were earlier shown to be chromosomally stable with modal chromosome number of 49. 29 A consistently delayed anaphase entry of cells overexpressing miR-125b implied that in absence of Mad1, SAC is activated transiently, delaying metaphase-to-anaphase transition. Notably, because MAD1 lacks its 3 0 UTR in the expression-vector, co-expression with miR-125b did not alter Mad1's ability to change the cellular phenotype. This also indicates that other known targets of miR-125b (like TP53) 30 might not have any role in the Mad1-mediated phenotype observed here. Our observations were underscored when Cdc20 overexpression along-with miR125b gave the same rescue pattern as Mad1. This was significant because Cdc20 is a direct target of SAC and hence, it confirmed the involvement of SAC. It is noteworthy that Cdc20 levels impact both mitotic slippage rate and cell fate. 29, 31, 32 Meanwhile, inhibiting endogenous miR-125b resulted in faster mitotic exit, possibly by inactivating SAC through increased Mad1 levels. This is reminiscent of a recent report that Mad1 upregulation might promote tumour miR-125b represses MAD1 expression S Bhattacharjya et al formation and manifest resistance to therapies. 16 It is wellknown that accelerated mitotic progression can induce CIN. 29, 16 Our data also reveal a higher incidence of chromosomal defects in presence of ectopic miR-125b, mostly in metaphase-to-anaphase transition. Cell viability too was considerably reduced by increased apoptotic death. Hence, it is conceivable that miR-125b up-or downregulation could both be harmful to cells as both give rise to CIN and lead to either accelerated proliferation or cell death, respectively (Figure 8 ). Therefore, a priori, in normal circumstances miR125b exerts it tumour suppressive role whenever Mad1 levels are elevated in response to some stimuli. This would be important to maintain the extremely delicate Mad1-Mad2 balance. In fact, this could be extended to all SAC genes-most of which are both up or downregulated in different tumours. 33 Although aneuploidy is recognized to promote tumorigenesis, it is also proposed to be tumour suppressive in some miR-125b represses MAD1 expression S Bhattacharjya et al contexts. 34 We speculate that segregation defects arising from miR-125b-induced Mad1 repression and transient SAC activation lead to accumulation of aneuploid cells and finally reduce cell growth and viability. Indeed, it was earlier reported that Mad1 expression is heightened in cancer cells and that this correlates with cellular proliferation. 35 At the molecular level, Mad1-bound and free-Mad2 are both essential to maintain SAC. Moreover, excess Mad1 can outdo Cdc20 in binding free-Mad2 owing to which Cdc20 can bind and activate APC/C. This leads to rapid mitotic exit and SAC abolishment. 15, 16 Through our study, we hypothesize that reduced Mad1 levels, due to excess miR-125b, increases free-Mad2 pool, which can bind more Cdc20 molecules, as a result of which APC/C remains inactive and cells are halted at metaphase.
In summary, (1) the SAC gene MAD1 is a novel target of miR-125b, (2) Mad1 downregulation brings about transient SAC activation and mitotic delay and (3) this delay gives rise to chromosomal abnormalities, presumable accumulation of which leads to apoptosis. All these cellular effects of miR125b appear to be Mad1-specific. These findings might help to understand the molecular mechanisms that contribute towards high degree of CIN associated with HNOC. The fact that HNOC frequently exhibits alterations in mitotic checkpoint genes mirrors the criticality of SAC integrity in this disease. 18 As alteration of Mad1 levels by miR-125b can cause distinct cellular events such as apoptosis, it can be comprehended that suppressing high Mad1 levels might prove to be therapeutic in HNOC. However, it is crucial to reckon that miR-125b has other known and unknown targets across the cell cycle whereas Mad1 regulation could also be controlled by hitherto unknown miRNAs. Hence, a systemic study of miRNAs involved in regulation of Mad1 and other SAC genes is warranted to fully understand the impact of miRNAs on SAC function, as well as on development and progression of HNOC.
Materials and Methods
Cell culture, synchronization, drug treatment and transfection. Human oral cancer cell lines UPCI:SCC084 and UPCI:SCC131 were kind gifts from Dr. Susanne M. Gollin (University of Pittsburgh, USA). HCT116 cell line was purchased from American Type Culture Collection (Manassas, VA, USA) and HepG2 cell line was gifted by Dr. Samit Adhya (Indian Institute of Chemical Biology, India). All cell lines were cultured in Dulbecco's Modified Eagle's Medium (DMEM; Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal calf serum and antibiotics (1% Pen Strep Glutamine and 0.006% Gentamicin, Invitrogen) at 37 1C in a 5% C0 2 incubator. For synchronization, cells were treated with thymidine (2.5 mM; USB, Cleveland, OH, USA) for 16 h followed by an 8-h release. A second thymidine treatment was given for another 22 h. Following this double thymidine block, cells were released in thymidine free complete medium and harvested at various time-points. Transient transfections were done with various plasmids and miRNA inhibitors in different cell lines using Lipofectamine 2000 reagent (Invitrogen) according to manufacturer's protocol. Except in case of synchronization experiments, all transient transfections were performed for 48 h. Transfection of synchronized cells was done 2 h before first thymidine addition. To induce mitotic arrest, cells were treated with the spindle disrupting drug, nocodazole (100 ng/ml, Sigma, St. Louis, MO, USA) for 16 h before second thymidine release. For induction of apoptosis by camptothecin, cells were treated with the drug (100 mg/ml, Sigma) for 48 h.
Plasmids and miRNA inhibitors. The cloning of human precursor miR125b is described by Ghose et al. 36 The same strategy was followed to clone the human precursor miR-133b (Chromosome 6: 52011721-52015839, þ strand). This clone will now be referred to as pSB-miR-133b. The MAD1-3 0 UTR (NM_003550.2, þ 2422 to þ 2727) was amplified from human genomic DNA with the primers listed in Supplementary Table S9 . This region was cloned into the linearized pMIR-REPORT vector (Applied Biosystems, Foster City, CA, USA) downstream of the Luc gene using the MluI and HindIII restriction sites (New England Biolabs, Beverly, MA, USA). This clone will henceforth be referred to as pSB-MAD1/3 0 UTRLuc. The mutant version of this clone was constructed using the primers listed in Supplementary Table S9 and Quikchange XL site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's protocol. This clone will be referred to as pSB-MAD1/3 0 UTRMutLuc. Full length FLAG-tagged Cdc20 expression plasmid pCDNA5/FRT/TO FLAG-CDC20 was a kind gift from Dr. Jonathon Pines (Gurdon Institute, Cambridge, UK). Full length GFP-tagged Mad1 expression plasmid pEGFP-C1-Mad1 was also gifted by Dr. Kuan-Teh Jeang (National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA). Anti-miR-125b (Ambion, Austin, TX, USA) was used at a final concentration of 20 nM or as indicated.
Quantitative real-time PCR. Total RNA from different cell lines, patient tissues and oral swab was isolated using TRIZOL (Invitrogen) according to manufacturer's protocol. 5 mg isolated RNA was treated with DNase (Promega, Madison, WI, USA) and 1 mg of the DNase-treated RNA was used for cDNA preparation using random hexamer (Invitrogen) and MMLV-RT (Promega). For miRNAs, 200 ng isolated RNA was used for cDNA preparation in a master mix miR-125b represses MAD1 expression S Bhattacharjya et al containing stem-loop primers specific for the desired miRNAs (Sigma), dNTPs (Invitrogen) and MMLV-RT (Promega). Real-time PCR was performed in the 7500 Fast Real-Time PCR System (Applied Biosystems) using power SYBR Green PCR Master Mix (Applied Biosystems). The comparative threshold cycle method (DDCt) was used to quantify relative amounts of product transcripts with GAPDH (for mRNAs) and hsa-miR-17-5p (for miRNAs) as endogenous reference controls. Primer sets for MAD1, BUB3 and GAPDH are listed in Supplementary Table S10. Fold activation values were calculated as mean of three independent experiments.
Western blotting and antibodies. Whole cell lysates having equal protein concentrations were resolved by SDS/PAGE (8-12% gel) and transferred onto a PVDF membrane (Millipore, Billerica, MA, USA). Various primary antibodies used are mouse monoclonal Mad1 (Millipore), mouse monoclonal cyclinB1 (Cell Signaling Technology, Beverly, MA, USA), rabbit polyclonal p-H3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit polyclonal H3 (Santa Cruz Biotechnology), mouse monoclonal Cdc20 (E-7, Santa Cruz Biotechnology), mouse monoclonal b-actin antibody (Sigma). Bands were detected using Super Signal West Pico chemiluminescent substrate (Thermo Scientific, Rockford, IL, USA) after treating with HRP-conjugated secondary antibody (Sigma).
Luciferase assay. Cells were lysed with luciferase cell culture lysis reagent supplied with the luciferase assay kit (Promega). After a short vortex, whole cell lysates were centrifuged at 4 1C at 13 000 r.p.m. for 2 min and 15-30 ml of supernatants was mixed with 30-60 ml of luciferase assay substrate. Luminescence was measured as relative luciferase unit in GLOMAX luminometer (Promega). Total protein concentration in each lysate was measured by Bio-Rad protein assay reagent (Bio-Rad Laboratories, Hercules, CA, USA) and then used to normalize the Luc activity of each lysate. Fold activation values were calculated as mean of three independent experiments.
Determination of MI. Synchronized UPCI:SCC084 or HCT116 cells were harvested at different time-points (as mentioned in respective cases) after thymidine release. They were then fixed with ice-cold acetomethanol (1 : 1) and stained with DAPI (4,6-diamidino-2-phenylindole) (Invitrogen). Frequencies of Cell cycle, cell survival and apoptotic assays. UPCI:SCC084 cells were synchronized and after release, approximately 10 6 cells were harvested at respective time-points and resuspended in 0.25 ml of cold phosphate-buffered saline (PBS). Cells were fixed by adding cold 70% ethanol dropwise into the samples, while vortexing gently and then incubated at 4 1C for minimum 24 h. After fixation, cells were resuspended in 1 ml PBS containing 100 mg/ml PI (Sigma) and 20 mg/ml RNase A (Invitrogen). Fixed cells were kept at room temperature for 40 min and then analysed by FACS (BD FACSARIA III, Becton-Dickinson, San Jose, CA, USA).
For annexin V-PI binding assay, UPCI:SCC084 cells were seeded at a density of 10 5 cells and transfected as mentioned. Apoptosis was measured at the indicated time-points using FITC AnnexinV Apoptosis Detection Kit I (BD Pharmingen, Franklin Lakes, NJ, USA) according to the manufacturer's protocol. Analysis was done by BD FACSARIA (Becton-Dickinson).
To measure caspase-3 cleavage, 10 5 UPCI:SCC084 cells were seeded and transiently transfected as mentioned. At indicated time-points, cells were fixed with 4% paraformaldehyde, permeabilized by fluorescence-activated cell sorter permeabilizing solution (BD Biosciences, San Jose, CA, USA). Before staining, permeabilized cells were treated with heat-inactivated 2% normal goat serum to block non-specific staining. Cells were then stained with normal rabbit sera or rabbit anti-human-cleaved caspase-3 antibody (Cell Signalling Technology). After washing, cells were incubated with multiple adsorbed FITC-conjugated secondary antibody (goat anti-rabbit immunoglobulin; BD Biosciences), washed and analysed by BD FACSARIA (Becton-Dickinson).
For colony formation assay, UPCI:SCC084 cells were counted and seeded at different cell densities (as mentioned) after which they were transiently transfected For MTT assay, 10 5 UPCI:SCC084 cells were seeded and transfected as mentioned. At the indicated time-points, MTT solution was added to each dish at a final concentration of 50 mg/ml. After 4-5 h incubation at 37 1C, MTT solution was removed and 500 ml DMSO was added to dissolve dye. 100 ml of each sample was taken in a 96-well plate and absorbance at 595 nm was measured using a microplate reader (355 Thermo Multiskan Ex, Thermo Scientific). Percent viability was calculated as a mean of three independent experiments.
Immunofluorescence. Synchronized UPCI:SCC084 cells were harvested at different time-points (as mentioned in respective cases) after thymidine release. They were then fixed with ice-cold acetomethanol (1 : 1) and permeabilized with 0.03% saponin (Calbiochem, Darmstadt, Germany). After blocking in 3% BSA, rabbit polyclonal antibody against p-H3 (Santa Cruz Biotechnology) was added. Secondary antibody conjugated with FITC (Sigma) was added and the nuclei were stained with DAPI (Invitrogen). Slides were observed under a fluorescence microscope (Leica DM 3000). Abnormal chromosomes were counted among 100-200 cells each time from three independent experiments and plotted as percent abnormality. Lagging chromosomes are observed as thread-like structures between the separating sets of chromatids at anaphase, which stain positive for p-H3-FITC.
Immunohistochemistry (IHC). About 3-5 mm paraffin-embedded sections of normal oral and primary HNOC tissues were deparaffinized and rehydrated in Figure 7 MAD1 expression negatively correlates with that of miR-125b in HNOC. (a) Reciprocal relation of miR-125b and MAD1 in HNOC tumours. Total RNA was isolated from primary HNOC tissues (n ¼ 25) and adjacent normal tissues (n ¼ 20). cDNA was prepared by stem-loop primers specific for miR-125b and miR-17-5p and subjected to RT-PCR. Values were normalized to those of miR-17-5p. For MAD1, the above RNA was reverse transcribed and cDNA was subjected to RT-PCR using MAD1-specific primers. GAPDH was used as endogenous control. DDCt values were calculated and data plotted in terms of log 2 of relative expressions. P-values are indicated. 'n' represents the number of tumour samples and circles represent outliers. (b) Representative images showing inverse relation between Mad1 and miR-125b in primary HNOC tissues. Paraffin-embedded tissues samples (in which miR-125b expression was found to be low and Mad1 expression was high and vice versa; n ¼ 16) were processed for IHC with antibody against Mad1, stained with 3,3 0 diaminobenzidine and counterstained with hematoxylin. Nuclei, which stained mild or deep brown represent moderate or high expression of Mad1, respectively. Blue/bluish-purple staining of nuclei represents low Mad1 expression. Images represent Â 20 magnification, while inset images represent Â 40 magnification. Scale bars represent 50 mm. T1, T2, T3, T4, T5 and T6 are representative tumour samples taken from six individual patients miR-125b represses MAD1 expression S Bhattacharjya et al gradient alcohol. Antigen retrieval was followed by blocking with 1% BSA, addition of mouse monoclonal antibody against Mad1 (Santa Cruz Biotechnology) and incubation overnight at 4 1C. Slides were developed using 3,3 0 diaminobenzidine as the chromogen after treating with HRP-conjugated secondary antibody (Sigma) and then counterstained with hematoxylin. Negative controls lacked primary antibody. Data were scored as described by Perrone et al.
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Tumour samples. Matched oral tumour (n ¼ 25) and normal (n ¼ 20) tissues were obtained from the archive samples of the hospital section, Chittaranjan National Cancer Institute (CNCI), Kolkata, India. For five tumour samples, adjacent-normal tissues were unavailable. Out of the 25 tumour samples, 16 were available as paraffin blocks for IHC study. Prior to sample collection, written informed consent was taken from each individual and approved by the Research Ethics Committee of CNCI. The pathological history of the tumours is provided in Supplementary Table S7 .
Bioinformatic and statistical analysis. Target prediction of miRNAs was done by miRBase (version 17) . Complementarity between MAD1-3 0 UTR and the seed sequence of miR-125b was obtained from RNAhybrid (version 2.1) 38 (http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/). Oncomine 4.4 research edition database 39 (http://www.oncomine.org/resource/login.html) was used for the data set of Mad1 overexpression in primary tumours. Cancer versus normal data sets of Mad1 overexpression with fold change Z1.5 and P-valuer0.05 were selected. Densitometric scanning for western blots was done by ImageJ software (http:// rsb.info.nih.gov/ij/index.html). SPSS 16.0 (SPSS Inc., Chicago, IL, USA; http:// www.spss.com) was used to perform Mann-Whitney t-test in order to determine significant differences between individual groups (normal and tumour) with respect to miR-125b and Mad1 expressions. Fisher's exact w Figure 8 Proposed model for the regulation of Mad1 and cell fate by miR-125b. On the left, it is shown that high expression of miR-125b downregulates Mad1 as a result of which SAC is transiently activated. This leads to mitotic delay and accumulation of chromosomal abnormalities. The cells fail to maintain themselves and finally undergo apoptotic cell death. On the right, the reverse situation is illustrated. Mad1 levels increase when miR-125b levels are low. As a result, SAC is overridden and premature mitotic exit occurs. This leads to elevated proliferation of cells miR-125b represses MAD1 expression S Bhattacharjya et al
